These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 20379224)
21. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
22. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. Carlson SK; Classic KL; Hadac EM; Dingli D; Bender CE; Kemp BJ; Russell SJ AJR Am J Roentgenol; 2009 Jan; 192(1):279-87. PubMed ID: 19098211 [TBL] [Abstract][Full Text] [Related]
23. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Domingo-Musibay E; Allen C; Kurokawa C; Hardcastle JJ; Aderca I; Msaouel P; Bansal A; Jiang H; DeGrado TR; Galanis E Cancer Gene Ther; 2014 Nov; 21(11):483-90. PubMed ID: 25394505 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626 [TBL] [Abstract][Full Text] [Related]
25. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138 [TBL] [Abstract][Full Text] [Related]
26. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. Penheiter AR; Wegman TR; Classic KL; Dingli D; Bender CE; Russell SJ; Carlson SK AJR Am J Roentgenol; 2010 Aug; 195(2):341-9. PubMed ID: 20651188 [TBL] [Abstract][Full Text] [Related]
27. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
28. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice. Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429 [TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299 [TBL] [Abstract][Full Text] [Related]
30. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644 [TBL] [Abstract][Full Text] [Related]
31. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. Penheiter AR; Dingli D; Bender CE; Russell SJ; Carlson SK J Gene Med; 2012; 14(9-10):590-7. PubMed ID: 23015290 [TBL] [Abstract][Full Text] [Related]
32. Oncolytic measles virus retargeting by ligand display. Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475 [TBL] [Abstract][Full Text] [Related]
33. Measles to the Rescue: A Review of Oncolytic Measles Virus. Aref S; Bailey K; Fielding A Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084 [TBL] [Abstract][Full Text] [Related]
34. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Mansfield DC; Kyula JN; Rosenfelder N; Chao-Chu J; Kramer-Marek G; Khan AA; Roulstone V; McLaughlin M; Melcher AA; Vile RG; Pandha HS; Khoo V; Harrington KJ Gene Ther; 2016 Apr; 23(4):357-68. PubMed ID: 26814609 [TBL] [Abstract][Full Text] [Related]
35. Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. Touchefeu Y; Khan AA; Borst G; Zaidi SH; McLaughlin M; Roulstone V; Mansfield D; Kyula J; Pencavel T; Karapanagiotou EM; Clayton J; Federspiel MJ; Russell SJ; Garrett M; Collins I; Harrington KJ Radiother Oncol; 2013 Jul; 108(1):24-31. PubMed ID: 23849174 [TBL] [Abstract][Full Text] [Related]
36. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609 [TBL] [Abstract][Full Text] [Related]
38. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Liu C; Russell SJ; Peng KW Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340 [TBL] [Abstract][Full Text] [Related]
39. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086 [TBL] [Abstract][Full Text] [Related]
40. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC Cancer Gene Ther; 2012 Dec; 19(12):839-44. PubMed ID: 23037808 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]